文献速递中毒与环境急症消化、代谢与肾脏急症

缓释注射剂与舌下丁丙诺啡治疗芬太尼相关阿片类使用障碍:一项随机临床试验的事后分析

Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2024-06-03
一句话结论在基线使用芬太尼的阿片类使用障碍患者中,皮下缓释丁丙诺啡相比舌下丁丙诺啡-纳洛酮,芬太尼阴性尿样比例更高(74.6% vs 61.9%,差12.7%,95%CI 9.6%-15.9%)。

该研究为一项24周随机双盲临床试验的事后分析,在美国35个门诊点纳入428例阿片类使用障碍患者,按基线尿芬太尼/去甲芬太尼阳性(123例)或阴性(305例)分组,比较皮下缓释丁丙诺啡(CAM2038)与舌下丁丙诺啡-纳洛酮。在芬太尼阳性亚组中,皮下丁丙诺啡组任何阿片类阴性尿样平均百分比为28.5%,舌下组为18.8%(差9.6%,95%CI -3.0%至22.3%);芬太尼阴性亚组分别为36.7%与30.6%(差6.1%,95%CI -1.9%至14.1%)。芬太尼阳性亚组中,皮下丁丙诺啡组芬太尼阴性尿样平均百分比为74.6%,舌下组为61.9%(差12.7%,95%CI 9.6%-15.9%)。所有组阿片戒断和渴求评分在治疗开始后迅速下降。作者认为皮下丁丙诺啡制剂可能更有效减少芬太尼使用。

要点

  • 芬太尼阳性亚组中,皮下缓释丁丙诺啡组芬太尼阴性尿样平均百分比为74.6%,舌下丁丙诺啡-纳洛酮组为61.9%(差12.7%,95%CI 9.6%-15.9%)。
  • 芬太尼阳性亚组中,任何阿片类阴性尿样平均百分比皮下组为28.5%,舌下组为18.8%(差9.6%,95%CI -3.0%至22.3%),未达统计学显著。
  • 芬太尼阴性亚组中,任何阿片类阴性尿样平均百分比皮下组为36.7%,舌下组为30.6%(差6.1%,95%CI -1.9%至14.1%),未达统计学显著。
  • 完成研究比例在芬太尼阳性亚组为60.2%(74/123),芬太尼阴性亚组为56.7%(173/305)。
  • 所有组阿片戒断和渴求评分在治疗开始后迅速下降。

适用人群与场景

  • 美国35个门诊点纳入的阿片类使用障碍患者,按基线尿芬太尼或去甲芬太尼阳性(123例)或阴性(305例)分组。
  • 芬太尼阳性亚组:皮下缓释丁丙诺啡64例,舌下丁丙诺啡-纳洛酮59例;平均(SD)年龄39.1(10.8)岁,男性75例(61.0%)。
  • 芬太尼阴性亚组:皮下缓释丁丙诺啡149例,舌下丁丙诺啡-纳洛酮156例;平均(SD)年龄38.1(11.1)岁,男性188例(61.6%)。

处置流程与药物剂量

  • 干预为皮下缓释丁丙诺啡(CAM2038)每周和每月皮下注射 vs 每日舌下丁丙诺啡-纳洛酮。
  • 研究访视:前12周每周尿检,第13至24周之间6次尿检。

研究设计与关键结果

  • 研究类型:24周随机双盲临床试验的事后分析,美国35个门诊点,2015年12月至2016年11月,纳入428例阿片类使用障碍患者,按基线尿芬太尼/去甲芬太尼阳性(123例)或阴性(305例)分组,比较皮下缓释丁丙诺啡(CAM2038)与舌下丁丙诺啡-纳洛酮。
  • 主要终点:芬太尼阳性亚组中,任何阿片类阴性尿样平均百分比皮下组28.5% vs 舌下组18.8%(差9.6%,95%CI -3.0%至22.3%);芬太尼阴性亚组中,皮下组36.7% vs 舌下组30.6%(差6.1%,95%CI -1.9%至14.1%);基线芬太尼状态和治疗分组的主效应显著。
  • 关键次要终点:芬太尼阳性亚组中,芬太尼阴性尿样平均百分比皮下组74.6% vs 舌下组61.9%(差12.7%,95%CI 9.6%-15.9%)。
  • 完成研究比例:芬太尼阳性亚组60.2%(74/123) vs 芬太尼阴性亚组56.7%(173/305)。
  • 所有组阿片戒断和渴求评分在治疗开始后迅速下降。

证据类型、等级与局限

  • 证据类型:随机双盲临床试验的事后分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在基线使用芬太尼的阿片类使用障碍患者中,丁丙诺啡似乎有效。
  • 作者认为,与芬太尼阴性亚组相比,芬太尼使用患者在试验期间阿片类阴性尿样更少。
  • 作者认为,皮下丁丙诺啡制剂可能更有效减少芬太尼使用。

指南或共识出处

  • 临床试验注册号:ClinicalTrials.gov NCT02651584。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Fentanyl has exacerbated the opioid use disorder (OUD) and opioid overdose epidemic. Data on the effectiveness of medications for OUD among patients using fentanyl are limited.

OBJECTIVE: To assess the effectiveness of sublingual or extended-release injection formulations of buprenorphine for the treatment of OUD among patients with and without fentanyl use.

DESIGN, SETTING, AND PARTICIPANTS: Post hoc analysis of a 24-week, randomized, double-blind clinical trial conducted at 35 outpatient sites in the US from December 2015 to November 2016 of sublingual buprenorphine-naloxone vs extended-release subcutaneous injection buprenorphine (CAM2038) for patients with OUD subgrouped by presence vs absence of fentanyl or norfentanyl in urine at baseline. Study visits with urine testing occurred weekly for 12 weeks, then 6 times between weeks 13 and 24. Data were analyzed on an intention-to-treat basis from March 2022 to August 2023.

INTERVENTION: Weekly and monthly subcutaneous buprenorphine vs daily sublingual buprenorphine-naloxone.

MAIN OUTCOMES AND MEASURES: Retention in treatment, percentage of urine samples negative for any opioids (missing values imputed as positive), percentage of urine samples negative for fentanyl or norfentanyl (missing values not imputed), and scores on opiate withdrawal scales and visual analog craving scales.

RESULTS: Of 428 participants, 123 (subcutaneous buprenorphine, n = 64; sublingual buprenorphine-naloxone, n = 59; mean [SD] age, 39.1 [10.8] years; 75 men [61.0%]) had evidence of baseline fentanyl use and 305 (subcutaneous buprenorphine, n = 149; buprenorphine-naloxone, n = 156; mean [SD] age, 38.1 [11.1] years; 188 men [61.6%]) did not have evidence of baseline fentanyl use. Study completion was similar between the fentanyl-positive (60.2% [74 of 123]) and fentanyl-negative (56.7% [173 of 305]) subgroups. The mean percentage of urine samples negative for any opioid were 28.5% among those receiving subcutaneous buprenorphine and 18.8% among those receiving buprenorphine-naloxone in the fentanyl-positive subgroup (difference, 9.6%; 95% CI, -3.0% to 22.3%) and 36.7% among those receiving subcutaneous buprenorphine and 30.6% among those receiving buprenorphine-naloxone in the fentanyl-negative subgroup (difference, 6.1%; 95% CI, -1.9% to 14.1%), with significant main associations of baseline fentanyl status and treatment group. In the fentanyl-positive subgroup, the mean percentage of urine samples negative for fentanyl during the study was 74.6% among those receiving subcutaneous buprenorphine vs 61.9% among those receiving sublingual buprenorphine-naloxone (difference, 12.7%; 95% CI, 9.6%-15.9%). Opioid withdrawal and craving scores decreased rapidly after treatment initiation across all groups.

CONCLUSIONS AND RELEVANCE: In this post hoc analysis of a randomized clinical trial of sublingual vs extended-release injection buprenorphine for OUD, buprenorphine appeared to be effective among patients with baseline fentanyl use. Patients with fentanyl use had fewer opioid-negative urine samples during the trial compared with the fentanyl-negative subgroup. These findings suggest that the subcutaneous buprenorphine formulation may be more effective at reducing fentanyl use.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02651584.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Nunes EV, Comer SD, Lofwall MR, et al. Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024. PMID: 38916892. doi:10.1001/jamanetworkopen.2024.17377

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。